Back to News & Events

Webinar Recording: How BARDA is Investing $2B to Combat COVID-19

Our fellow BARDA DRIVe Accelerator, Life Science Washington Institute, has made available the recording of their recent webinar with BARDA detailing how the agency in investing to company COVID-19. Click the image to the webinar recording from June 4, 2020

Visit the Life Science Washington Institute webinar page for more information and links referenced in the webinar. https://www.lswinstitute.org/programs/drive-webinar/

Related Stories

WP_Query Object
(
    [query] => Array
        (
            [post_type] => post
            [posts_per_page] => 3
            [post_status] => publish
            [orderby] => rand
        )

    [query_vars] => Array
        (
            [post_type] => post
            [posts_per_page] => 3
            [post_status] => publish
            [orderby] => rand
            [error] => 
            [m] => 
            [p] => 0
            [post_parent] => 
            [subpost] => 
            [subpost_id] => 
            [attachment] => 
            [attachment_id] => 0
            [name] => 
            [pagename] => 
            [page_id] => 0
            [second] => 
            [minute] => 
            [hour] => 
            [day] => 0
            [monthnum] => 0
            [year] => 0
            [w] => 0
            [category_name] => 
            [tag] => 
            [cat] => 
            [tag_id] => 
            [author] => 
            [author_name] => 
            [feed] => 
            [tb] => 
            [paged] => 0
            [meta_key] => 
            [meta_value] => 
            [preview] => 
            [s] => 
            [sentence] => 
            [title] => 
            [fields] => 
            [menu_order] => 
            [embed] => 
            [category__in] => Array
                (
                )

            [category__not_in] => Array
                (
                )

            [category__and] => Array
                (
                )

            [post__in] => Array
                (
                )

            [post__not_in] => Array
                (
                )

            [post_name__in] => Array
                (
                )

            [tag__in] => Array
                (
                )

            [tag__not_in] => Array
                (
                )

            [tag__and] => Array
                (
                )

            [tag_slug__in] => Array
                (
                )

            [tag_slug__and] => Array
                (
                )

            [post_parent__in] => Array
                (
                )

            [post_parent__not_in] => Array
                (
                )

            [author__in] => Array
                (
                )

            [author__not_in] => Array
                (
                )

            [search_columns] => Array
                (
                )

            [ignore_sticky_posts] => 
            [suppress_filters] => 
            [cache_results] => 1
            [update_post_term_cache] => 1
            [update_menu_item_cache] => 
            [lazy_load_term_meta] => 1
            [update_post_meta_cache] => 1
            [nopaging] => 
            [comments_per_page] => 50
            [no_found_rows] => 
            [order] => 
        )

    [tax_query] => WP_Tax_Query Object
        (
            [queries] => Array
                (
                )

            [relation] => AND
            [table_aliases:protected] => Array
                (
                )

            [queried_terms] => Array
                (
                )

            [primary_table] => wp_posts
            [primary_id_column] => ID
        )

    [meta_query] => WP_Meta_Query Object
        (
            [queries] => Array
                (
                )

            [relation] => 
            [meta_table] => 
            [meta_id_column] => 
            [primary_table] => 
            [primary_id_column] => 
            [table_aliases:protected] => Array
                (
                )

            [clauses:protected] => Array
                (
                )

            [has_or_relation:protected] => 
        )

    [date_query] => 
    [request] => SELECT SQL_CALC_FOUND_ROWS  wp_posts.ID
					 FROM wp_posts 
					 WHERE 1=1  AND wp_posts.post_type = 'post' AND ((wp_posts.post_status = 'publish'))
					 
					 ORDER BY RAND()
					 LIMIT 0, 3
    [posts] => Array
        (
            [0] => WP_Post Object
                (
                    [ID] => 4439
                    [post_author] => 3
                    [post_date] => 2024-07-30 15:29:07
                    [post_date_gmt] => 2024-07-30 19:29:07
                    [post_content] => 

CFB Client, IAMBIC has been awarded approximately $1M in grant funding from the National Science Foundation Small Business Innovation Research program. IAMBIC is an innovative shoe company disrupting the centuries-old footwear industry with their sizeless, precision-fit footwear driven by proprietary AI algorithms. This substantial funding from NSF enables IAMBIC to scale its cutting-edge precision-fit shoe design and manufacturing.

The Center for Biotechnology and its accelerator programs have been instrumental in assisting IAMBIC with their SBIR pursuits and commercialization development.

Read more about IAMBIC and their recent funding here.

[post_title] => IAMBIC Receives $1 Million NSF SBIR Phase II Grant [post_excerpt] => This substantial funding from NSF enables IAMBIC to scale its operations. [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => iambic-receives-1-million-nsf-sbir-phase-ii-grant [to_ping] => [pinged] => [post_modified] => 2024-08-09 15:38:43 [post_modified_gmt] => 2024-08-09 19:38:43 [post_content_filtered] => [post_parent] => 0 [guid] => https://centerforbiotechnology.org/?p=4439 [menu_order] => 0 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [1] => WP_Post Object ( [ID] => 3660 [post_author] => 3 [post_date] => 2021-03-22 15:00:43 [post_date_gmt] => 2021-03-22 15:00:43 [post_content] =>

innovosource is partnering with Philips Image Guided Therapy Devices to identify partnership opportunities related to three specific technical challenges.

The goal is to connect motivated, industry partners with existing partnership nodes at research institutions to engage and initiate long-lasting relationships. Positive outcomes could result in company-funded POC projects, licensing, startup investment, and/or research partnerships.

This process is open and free to participate to all research institution partnership nodes (tech commercialization, gap funds/accelerators, corporate relations, research centers, faculty).

Learn more here: https://innovosource.lpages.co/bridge/

[post_title] => BRIDGE: University-Industry Proof of Concept Program [post_excerpt] => [post_status] => publish [comment_status] => open [ping_status] => open [post_password] => [post_name] => bridge-university-industry-proof-of-concept-program [to_ping] => [pinged] => [post_modified] => 2021-03-22 15:01:13 [post_modified_gmt] => 2021-03-22 15:01:13 [post_content_filtered] => [post_parent] => 0 [guid] => https://centerforbiotechnology.org/?p=3660 [menu_order] => 52 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [2] => WP_Post Object ( [ID] => 4069 [post_author] => 4 [post_date] => 2023-04-04 14:21:12 [post_date_gmt] => 2023-04-04 14:21:12 [post_content] =>

The Office of the President, Office of the Provost, Office of the Senior Vice President for Health Sciences, and Office of the Vice President for Research invite applications for a seed grant program to fund collaborative efforts between biomedical scientists at SBU seeking to apply to externally funded research and training initiatives.

This seed grant program will award proposals in the following areas of interest:
- Brain, Behavior, Neurodegenerative and Neuropsychiatric Disorders
Cancer
- Development, Aging, and Life Span
- Drug Development, from Chemistry to Diagnostics and Therapies
- Environmental Health, Climate Change and Human Health
- Immunology and Infectious Diseases
- Metabolism, Obesity, Diabetes, and Cardiovascular Disorders
- Technology, Computation, Biology, Medicine, and Regenerative Medicine

The program will fund up to five multidisciplinary teams that commit to submitting proposals for medium/large scale grants (i.e., >$3M for research grants and >$2M for training grants) in the following categories: multi-PI grants, center grants, instrumentation grants, and training grants. Awarded projects will receive up to $100,000 for a maximum award period of two years.

Eligibility Requirements
All PIs must be current, full-time, tenured or tenure track faculty at Stony Brook University
Applicants can only be PI on one application and Co-PI on one application. There is a limit of four Co-PIs on any application.

Applications due May 8, 2023 at 11:59 PM EST via the application submission portal.

Full details here: https://www.stonybrook.edu/commcms/proposal-development/funding/OVPR_Seed_Grant_Program/Biomedical_Sciences_Innovation_Fund.php

[post_title] => SBU Faculty: Biomedical Sciences Innovation Fund [post_excerpt] => Stony Brook University Faculty are invited to apply for seed grant program to fund collaborative efforts between biomedical scientists at SBU seeking to apply to externally funded research and training initiatives. [post_status] => publish [comment_status] => open [ping_status] => open [post_password] => [post_name] => sbu-faculty-biomedical-sciences-innovation-fund [to_ping] => [pinged] => [post_modified] => 2023-07-10 12:39:43 [post_modified_gmt] => 2023-07-10 16:39:43 [post_content_filtered] => [post_parent] => 0 [guid] => https://centerforbiotechnology.org/?p=4069 [menu_order] => 4 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [3] => WP_Post Object ( [ID] => 2865 [post_author] => 3 [post_date] => 2017-11-14 14:49:21 [post_date_gmt] => 2017-11-14 14:49:21 [post_content] => Codagenix, Inc., a clinical stage, venture and public-sector-funded small business, announced it has secured an additional $3M in funding in support of its live-attenuated Respiratory Syncytial Virus (RSV) vaccine candidate that was developed in collaboration with National Institute of Allergy and Infectious Diseases (NIAID), a part of NIH. The public funding to Codagenix is via a Phase II SBIR grant for $1.5M to support the pre-clinical manufacturing of the vaccine candidate. The private funding of $1.5M was provided by TopSpin Partners to support a Phase I trial to demonstrate safety and immunogenicity in aged volunteers. The two funding source were not linked; however, both are dedicated to supporting Codagneix’s RSV vaccine through a Phase I trial. Clinical Trial material of Codagenix RSV Vaccine candidate is currently being manufactured with a Phase I targeted for Q3- or Q4-2018. “Codagenix is an incredible example of a company rooting in our expanding bioecosystem, growing from a startup out of Stony Brook University into a clinical stage company” stated Dr. Clinton Rubin, Director of the New York State Center for Biotechnology at Stony Brook University. “The Center for Biotechnology is proud to provide ongoing support for the work they are doing through our various programs including the Applied Research and Development awards and the Long Island Bioscience Hub funding initiatives. “We are wrapping up a Phase I with our live-attenuated Influenza Vaccine in Q1-2018 and are very much looking forward to adding a second clinical-stage compound to our pipeline with RSV,” stated Codegenix COO J. Robert Coleman. “We are grateful to our investors and partners like the Center for Biotechnology that understand our vision and continually support our development at these early stages. We are demonstrating that our platform provides a rational means to design vaccines against a range targets – yielding candidates suitable for full clinical development.” Codagenix has raised a total of $10M since 2015 – with its influenza vaccine candidate currently in Phase I and a pre-clinical pipeline that includes Zika, Dengue, and Agricultural targets in addition to RSV. RSV is a virus that targets newborns and the elderly, with an estimated market size of $2 Billion for a potential RSV vaccine. About Codagenix Inc. Codagenix Inc., a biotechnology company on Long Island, New York, is developing live attenuated vaccines using a "disruptive" software-based rational design algorithm that is unlike previous vaccine "platforms”. By leveraging the redundancy in the genetic code (various codons exist at the gene level to encode the same amino acid at the protein level), the Codagenix algorithm re-structures viral genomes into a sub-optimal genetic code. The so-called “deoptimized” viruses have resulted in highly attenuated vaccine strains that are effective at greatly reduced doses, because they present every antigen of the pathogen, while being 100% identical to the target pathogen at the protein level. The Codagenix pipeline of vaccines includes Influenza, respiratory syncytial virus (RSV), Zika, Dengue, foot-and-mouth disease virus (FMDV), pathogenic E. coli, and other pathogens. Codagenix has also been supported the Center for Biotechnology at Stony brook University which is a New York State Center for Advanced Technology and NIH-designated Research, Evaluation and Commercialization Hub (REACH) [post_title] => CFB Client Secures $3M Public and Private Investment [post_excerpt] => Codagenix, Inc., has secured an additional $3M in funding in support of its live-attenuated Respiratory Syncytial Virus (RSV) vaccine candidate that was developed in collaboration with National Institute of Allergy and Infectious Diseases (NIAID), a part of NIH. [post_status] => publish [comment_status] => open [ping_status] => open [post_password] => [post_name] => cfb-client-secures-3m-public-and-private-investment [to_ping] => [pinged] => [post_modified] => 2017-11-14 14:49:44 [post_modified_gmt] => 2017-11-14 14:49:44 [post_content_filtered] => [post_parent] => 0 [guid] => http://centerforbiotechnology.org/?p=2865 [menu_order] => 136 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) ) [post_count] => 4 [current_post] => -1 [before_loop] => 1 [in_the_loop] => [post] => WP_Post Object ( [ID] => 4439 [post_author] => 3 [post_date] => 2024-07-30 15:29:07 [post_date_gmt] => 2024-07-30 19:29:07 [post_content] =>

CFB Client, IAMBIC has been awarded approximately $1M in grant funding from the National Science Foundation Small Business Innovation Research program. IAMBIC is an innovative shoe company disrupting the centuries-old footwear industry with their sizeless, precision-fit footwear driven by proprietary AI algorithms. This substantial funding from NSF enables IAMBIC to scale its cutting-edge precision-fit shoe design and manufacturing.

The Center for Biotechnology and its accelerator programs have been instrumental in assisting IAMBIC with their SBIR pursuits and commercialization development.

Read more about IAMBIC and their recent funding here.

[post_title] => IAMBIC Receives $1 Million NSF SBIR Phase II Grant [post_excerpt] => This substantial funding from NSF enables IAMBIC to scale its operations. [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => iambic-receives-1-million-nsf-sbir-phase-ii-grant [to_ping] => [pinged] => [post_modified] => 2024-08-09 15:38:43 [post_modified_gmt] => 2024-08-09 19:38:43 [post_content_filtered] => [post_parent] => 0 [guid] => https://centerforbiotechnology.org/?p=4439 [menu_order] => 0 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [comment_count] => 0 [current_comment] => -1 [found_posts] => 260 [max_num_pages] => 87 [max_num_comment_pages] => 0 [is_single] => [is_preview] => [is_page] => [is_archive] => [is_date] => [is_year] => [is_month] => [is_day] => [is_time] => [is_author] => [is_category] => [is_tag] => [is_tax] => [is_search] => [is_feed] => [is_comment_feed] => [is_trackback] => [is_home] => 1 [is_privacy_policy] => [is_404] => [is_embed] => [is_paged] => [is_admin] => [is_attachment] => [is_singular] => [is_robots] => [is_favicon] => [is_posts_page] => [is_post_type_archive] => [query_vars_hash:WP_Query:private] => 325c4f9f1aebaa5ec90666fa54175ba0 [query_vars_changed:WP_Query:private] => [thumbnails_cached] => [allow_query_attachment_by_filename:protected] => [stopwords:WP_Query:private] => [compat_fields:WP_Query:private] => Array ( [0] => query_vars_hash [1] => query_vars_changed ) [compat_methods:WP_Query:private] => Array ( [0] => init_query_flags [1] => parse_tax_query ) )

IAMBIC Receives $1 Million NSF SBIR Phase II Grant

More Information

BRIDGE: University-Industry Proof of Concept Program

More Information

SBU Faculty: Biomedical Sciences Innovation Fund

More Information

CFB Client Secures $3M Public and Private Investment

More Information